This project is developing minimally invasive biomarkers for cancer detection, with an emphasis on circulating tumour DNA (ctDNA) for melanoma and colorectal cancer.  These cancers have been selected because their incidence in New Zealand is amongst the highest in the world.

The markers will reduce reliance on highly specialised imaging techniques only available at tertiary level hospitals. This increases health equity by removing barriers to rural communities (including marae-based care).  Importantly, development of markers for these cancers will include ways to best integrate their use into the existing and emerging cancer screening programmes.

Read more about the project at Improving life and outcomes for cancer patients.

 

CtDNA for better cancer management: the application of precision oncology to the New Zealand healthcare system

Science leader and principal investigator:

Co-principal investigators:

Associate investigators:

 

Conferences and symposia

 

Related news